Dr. Simeone on Benefit of Neoadjuvant Gemcitabine in Pancreatic Cancer

Video

In Partnership With:

Diane M. Simeone, MD, discusses the benefit of using a gemcitabine “sandwich approach” in patients with resectable pancreatic cancer.

Diane M. Simeone, MD, Laura and Issac Perlmutter Professor of Surgery in the Department of Surgery; professor in the Department of Pathology; associate director of Translational Research at Perlmutter Cancer Center; professor in the Department of Pathology at NYU Grossman School of Medicine; and director of the Pancreatic Cancer Center of NYU Langone Health, discusses the benefit of using a gemcitabine “sandwich approach” in patients with resectable pancreatic cancer.

A couple studies were read out at the 2020 Gastrointestinal Cancers Symposium that are relevant to this space, says Simeone. For example, a phase 2 study that came from Europe enrolled patients with resectable or borderline resectable disease and randomized those patients to receive either surgery and adjuvant gemcitabine or neoadjuvant gemcitabine, surgery, and then gemcitabine afterward, almost like a sandwich approach, says Simeone.

The preliminary data suggest that patients who were treated with neoadjuvant gemcitabine and then surgery followed by more gemcitabine seemed to have improved overall survival, concludes Simeone.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD